Literature DB >> 6607080

Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells.

N E Kay, J M Zarling.   

Abstract

This study was undertaken to gain further insight into the severely impaired natural killer (NK) activity we and others have previously observed in patients with chronic lymphocytic leukemia (CLL). Normal individuals' NK cells are large granular lymphocytes (LGL) that (A) bind to and lyse NK-sensitive cells, including K562, (B) express receptors for the Fc portion of IgG (FcR+ cells), and (C) express cell surface antigens reactive with monoclonal antibodies OKM1, 9.6, and OKT11A. We thus examined lymphocytes depleted of monocytes and B cells, from 6 CLL patients and 6 normal individuals, that were identified on the basis of binding to K562, expressing OKM1, or expressing receptors for the Fc portion of IgG. In the CLL patients studied, lymphocytes that bind to K562 cells, as well as OKM1+ cells isolated by fluorescence activated cell sorting, were morphologically similar to LGL of normal individuals, with the exception that more than 75% of the patients' cells were deficient in azurophilic cytoplasmic granules, which typify normal individuals' LGL. Furthermore, although the percentages of the patients' FcR+ cells reactive with OKT11A, 9.6 and OKM1 were very similar to those of normals, the majority of the patients' FcR+ cells were deficient in azurophilic granules and lacked NK activity. These findings indicate that the impaired NK activity in CLL patients is associated with cells that are phenotypically and morphologically NK cells, but which lack azurophilic granules that are thought to play a role in NK-mediated lysis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6607080

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

1.  Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy.

Authors:  Caroline Veuillen; Thérèse Aurran-Schleinitz; Rémy Castellano; Jérôme Rey; Françoise Mallet; Florence Orlanducci; Laurent Pouyet; Sylvaine Just-Landi; Diane Coso; Vadim Ivanov; Xavier Carcopino; Réda Bouabdallah; Yves Collette; Cyril Fauriat; Daniel Olive
Journal:  J Clin Immunol       Date:  2012-02-09       Impact factor: 8.317

2.  Tumoricidal effects of activated macrophages in a mouse model of chronic lymphocytic leukemia.

Authors:  Qing-Li Wu; Ilia N Buhtoiarov; Paul M Sondel; Alexander L Rakhmilevich; Erik A Ranheim
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

3.  Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.

Authors:  Asher A Chanan-Khan; Kasyapa Chitta; Noreen Ersing; Aneel Paulus; Aisha Masood; Taimur Sher; Abhisek Swaika; Paul K Wallace; Terry L Mashtare; Greg Wilding; Kelvin Lee; Myron S Czuczman; Ivan Borrello; Naveen Bangia
Journal:  Br J Haematol       Date:  2011-10-20       Impact factor: 6.998

4.  Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia.

Authors:  Emily M McWilliams; Jennifer M Mele; Carolyn Cheney; Elizabeth A Timmerman; Faraz Fiazuddin; Ethan J Strattan; Xiaokui Mo; John C Byrd; Natarajan Muthusamy; Farrukh T Awan
Journal:  Oncoimmunology       Date:  2016-09-09       Impact factor: 8.110

5.  Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Thomas J Kipps; Ian W Flinn; Maureen Cooper; Olatoyosi Odenike; Jennifer Bendiske; John Rediske; Sanela Bilic; Jyotirmoy Dey; Johan Baeck; Susan O'Brien
Journal:  Leuk Lymphoma       Date:  2012-06-12

6.  Elevated absolute NK cell counts in peripheral blood predict good prognosis in chronic lymphocytic leukemia.

Authors:  Wen-Ting Wang; Hua-Yuan Zhu; Yu-Jie Wu; Yi Xia; Jia-Zhu Wu; Wei Wu; Jin-Hua Liang; Li Wang; Lei Fan; Jian-Yong Li; Wei Xu
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-03       Impact factor: 4.553

7.  Human NK cells activated by EBV+ lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells.

Authors:  Diego Sánchez-Martínez; Gemma Azaceta; Aura Muntasell; Nacho Aguiló; David Núñez; Eva M Gálvez; Javier Naval; Alberto Anel; Luis Palomera; Carlos Vilches; Isabel Marzo; Martín Villalba; Julián Pardo
Journal:  Oncoimmunology       Date:  2015-01-09       Impact factor: 8.110

8.  NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors.

Authors:  Alexander W MacFarlane; Mowafaq Jillab; Mitchell R Smith; R Katherine Alpaugh; Marion E Cole; Samuel Litwin; Michael M Millenson; Tahseen Al-Saleem; Adam D Cohen; Kerry S Campbell
Journal:  Oncoimmunology       Date:  2017-05-19       Impact factor: 8.110

9.  Generation and preclinical characterization of a Fc-optimized GITR-Ig fusion protein for induction of NK cell reactivity against leukemia.

Authors:  Benjamin Joachim Schmiedel; Antje Werner; Julia Steinbacher; Tina Nuebling; Corina Buechele; Ludger Grosse-Hovest; Helmut Rainer Salih
Journal:  Mol Ther       Date:  2013-02-05       Impact factor: 11.454

10.  Loss of natural killer activity as an indicator of relapse in acute leukaemia.

Authors:  J A Tratkiewicz; J Szer
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.